Related Experiment Video

Updated: Sep 26, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Coronary stenting in stable patients: identification of a low-risk subgroup that may not require adjunctive

Tift Mann1, Roberto J Cubeddu, Laura Raynor

  • 1Wake Heart Center, Raleigh, North Carolina 27610, USA. wakeheartresearch@msn.com

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|March 26, 2003
PubMed

Insights

Elective coronary stenting may not require additional antiplatelet therapy for select patients without diabetes. This study found similar outcomes for patients receiving clopidogrel, abciximab, or no adjunctive therapy.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • Coronary stenting is a common procedure for treating coronary artery disease.
  • The role of adjunctive antiplatelet therapy in elective coronary stenting for patients without diabetes is not fully established.

Purpose of the Study:

  • To prospectively evaluate the efficacy and safety of adjunctive antiplatelet therapy during elective coronary stenting in patients without insulin-requiring diabetes.

Main Methods:

  • A prospective randomized trial involving 300 patients without insulin-requiring diabetes undergoing elective coronary stenting.
  • Patients were randomized into three groups: clopidogrel pretreatment, adjunctive abciximab, or control (no adjunctive therapy).
  • Outcomes assessed included procedural success, death, and major adverse coronary events (MACEs) at 30 days and 1 year.

Main Results:

  • Stenting success rate was 98% with no reported deaths across all groups.
  • No significant differences in 30-day or 1-year MACEs were observed among the clopidogrel, abciximab, and control groups.
  • A subgroup of 109 patients with specific lesion types and short procedure times experienced no postprocedure myocardial infarction or 30-day MACE.

Conclusions:

  • Elective coronary stenting can be safely performed without adjunctive antiplatelet therapy in carefully selected patients without diabetes.
  • Patients with type A/B1 lesions and short guidewire times may represent a subgroup that can safely forego additional antiplatelet agents.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...